Untitled

Han, Ho; Jung, Jeyon

doi:10.15187/adr.2019.02.32.1.115

Cited by 6 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4A). This trend is probably attributable to the decrease in physical activity and increase in obesity due to social distancing owing to SARS-CoV-2 pandemic [10]. This trend shows a similar pattern for hypo-HDLcholesterolemia and hypertriglyceridemia.…”

Section: Discussionmentioning

confidence: 70%

Dyslipidemia Fact Sheet in South Korea, 2022

Jin,

Shim,

Kim

et al. 2023

Diabetes Metab J

View full text Add to dashboard Cite

Background: This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name Dyslipidemia Fact Sheet 2022.Methods: We analyzed the lipid profiles, age-standardized and crude prevalence, management status of hypercholesterolemia and dyslipidemia, and health behaviors among Korean adults aged ≥20 years, using the Korea National Health and Nutrition Examination Survey data between 2007 and 2020.Results: In South Korea, the crude prevalence of hypercholesterolemia (total cholesterol ≥240 mg/dL or use of a lipid-lowering drug) in 2020 was 24%, and the age-standardized prevalence of hypercholesterolemia more than doubled from 2007 to 2020. The crude treatment rate was 55.2%, and the control rate was 47.7%. The crude prevalence of dyslipidemia—more than one out of three conditions (low-density lipoprotein cholesterol ≥160 or the use of a lipid-lowering drug, triglycerides ≥200, or high-density lipoprotein cholesterol [HDL-C] [men and women] <40 mg/dL)—was 40.2% between 2016 and 2020. However, it increased to 48.2% when the definition of hypo-HDL-cholesterolemia in women changed from <40 to <50 mg/dL.Conclusion: Although the prevalence of hypercholesterolemia and dyslipidemia has steadily increased in South Korea, the treatment rate remains low. Therefore, continuous efforts are needed to manage dyslipidemia through cooperation between the national healthcare system, patients, and healthcare providers.

show abstract

Section: Discussionmentioning

confidence: 70%

Dyslipidemia Fact Sheet in South Korea, 2022

Jin,

Shim,

Kim

et al. 2023

Diabetes Metab J

View full text Add to dashboard Cite

show abstract

“…At each health screening period, the fatty liver index (FLI) was calculated for each participant using the following formula: The FLI efficiently identifies NAFLD in European and Asian populations, and previous studies also adopted FLI in the operational definition of steatotlic liver disease status. [22][23][24][25] MASLD was defined as steatotlic liver disease (FLI≥60) [26] and the presence of at least one of the following cardiometabolic risk factors: body mass index (BMI) ≥23 kg/m 2 or waist circumference ≥90 cm (for men) and ≥85 cm (for women) [27], fasting serum glucose ≥100 mg/dL or a history of antidiabetic drug prescription or type 2 diabetes, blood pressure ≥130/85 mm Hg or a history of antihypertensive drug prescription, triglycerides ≥150 mg/dL or a history of lipid-lowering drug prescription, and high-density lipoprotein cholesterol ≤40 mg/dL (for men) and ≤50 mg/dL (for women). [20] We created categories as follows: (…”

Section: Classification Of Change In Masld Statusmentioning

confidence: 99%

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

Jeong,

Oh,

Ahn

et al. 2024

Clin Mol Hepatol

View full text Add to dashboard Cite

Background/Aims: To determine the association between evolutionary changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status and the risk of hepatocellular carcinoma (HCC) in a nationwide population-based cohort.Methods: Information on study participants were derived from the Korea National Health Insurance Service database. The study population consisted of 5,080,410 participants who underwent two consecutive biennial health screenings between 2009 and 2012. All participants were followed up until HCC, death, or 31 December 2020. Association of evolutionary changes in MASLD status as assessed by fatty liver index and cardiometabolic risk factors, including persistent non-MASLD, resolved MASLD, incident MASLD, and persistent MASLD, with HCC risk was evaluated using the multivariable-adjusted Cox proportional hazards regression.Results: Among the 5,080,410 participants with 39,910,331 person-years of follow-up, 4,801 participants developed HCC. The incidence of HCC in participants with resolved, incident, and persistent MASLD was approximately 2.2-, 2.3-, and 4.7-fold higher, respectively, than that in those with persistent non-MASLD among the Korean adult population. When stratifying the participants according to the evolutionary change in MASLD status, persistent (adjusted hazard ratio [aHR], 2.94; 95% confidence interval [CI], P<0.001), incident (aHR, 1.85; 95% CI, P<0.001), and resolved MASLD (aHR, 1.33; 95% CI, P<0.001) had an increased risk of HCC than that of persistent non-MASLD. Conclusions:The evolutionary changes in MASLD were associated with the differential risk of HCC independent of metabolic risk factors and concomitant medications, providing additional information on the risk of HCC stratification in patients with MASLD.

show abstract

“…Annual screening (Expert opinion, General) for diabetes should be conducted for adults aged ≥35 and adults aged ≥19 with risk factors (Others, General) using fasting plasma glucose, 1, and abdominal obesity (waist circumference ≥90 cm for men, ≥85 cm for women) has been added compared to the previous guidelines. Owing to the recent increase in the prevalence of prediabetes, diabetes, obesity, and abdominal obesity among young adults under the age of 40 [1,7], there have been suggestions for a change in previous screening criteria for diabetes (adults aged ≥40 and adults aged ≥30 years with risk factors) [2]. The Committee of Clinical Practice Guidelines of the KDA conducted a cross-sectional study on the age for diabetes screening in adults aged ≥20 years using data from the Korean National Health and Nutrition Examination Survey (KNHANES, 2016 to 2020) and the Korean National Health Insurance Service sample cohort (2012 to 2017) [3].…”

Section: Screening For Diabetes Mellitusmentioning

confidence: 99%

2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association

Choi,

Lee,

Moon

et al. 2023

Diabetes Metab J

View full text Add to dashboard Cite

In May 2023, the Committee of Clinical Practice Guidelines of the Korean Diabetes Association published the revised clinical practice guidelines for Korean adults with diabetes and prediabetes. We incorporated the latest clinical research findings through a comprehensive systematic literature review and applied them in a manner suitable for the Korean population. These guidelines are designed for all healthcare providers nationwide, including physicians, diabetes experts, and certified diabetes educators who manage patients with diabetes or individuals at risk of developing diabetes. Based on recent changes in international guidelines and the results of a Korean epidemiological study, the recommended age for diabetes screening has been lowered. In collaboration with the relevant Korean medical societies, recently revised guidelines for managing hypertension and dyslipidemia in patients with diabetes have been incorporated into this guideline. An abridgment containing practical information on patient education and systematic management in the clinic was published separately.

show abstract

Untitled

Cited by 6 publications

References 6 publications

Dyslipidemia Fact Sheet in South Korea, 2022

Dyslipidemia Fact Sheet in South Korea, 2022

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association

Contact Info

Product

Resources

About